Acer Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Acer Therapeutics' is Chris Schelling, benoemd in Dec2013, heeft een ambtstermijn van 9.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 834.28K, bestaande uit 59.9% salaris en 40.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 11.09% van de aandelen van het bedrijf, ter waarde € 2.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 6.2 jaar.

Belangrijke informatie

Chris Schelling

Algemeen directeur

US$834.3k

Totale compensatie

Percentage CEO-salaris	59.9%
Dienstverband CEO	9.9yrs
Eigendom CEO	11.1%
Management gemiddelde ambtstermijn	4.2yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Schelling's beloning veranderd ten opzichte van Acer Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$834k	US$500k	-US$26m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$20m
Dec 31 2021	US$552k	US$436k	-US$15m
Sep 30 2021	n/a	n/a	-US$17m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$676k	US$436k	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	US$1m	US$436k	-US$29m
Sep 30 2019	n/a	n/a	-US$33m
Jun 30 2019	n/a	n/a	-US$31m
Mar 31 2019	n/a	n/a	-US$25m
Dec 31 2018	US$550k	US$400k	-US$21m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$585k	US$117k	-US$14m
Sep 30 2017	n/a	n/a	-US$12m
Jun 30 2017	n/a	n/a	-US$11m
Mar 31 2017	n/a	n/a	-US$9m
Dec 31 2016	US$469k	US$469k	-US$7m

Compensatie versus markt: De totale vergoeding ($USD 834.28K ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 503.65K ).

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Schelling (47 yo)

9.9yrs

Tenure

US$834,280

Compensatie

Mr. Christopher Schelling, also known as Chris, Founded Acer Therapeutics Inc. in December 2013 and has been its President and Chief Executive Officer since September 2017 and served as its Chief Operating...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Schelling	Founder	9.9yrs	US$834.28k	11.09% € 2.2m
Harry Palmin	Chief Financial Officer	7.8yrs	US$592.59k	0.51% € 101.5k
Adrian Quartel	Chief Medical Officer	1.8yrs	US$857.63k	0% € 0
Tanya Hayden	Chief Operating Officer	1.4yrs	geen gegevens	geen gegevens
John Klopp	Chief Technical Officer	4.2yrs	geen gegevens	geen gegevens
Donald Joseph	Chief Legal Officer & Secretary	5.6yrs	US$490.28k	geen gegevens
Bernie Paul	Chief People Officer	3.1yrs	geen gegevens	geen gegevens
Jefferson Davis	Chief Business Officer	2.8yrs	US$634.80k	0.29% € 58.2k
Jason Kneeland	VP of Finance & Controller	6yrs	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van P6NP wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Schelling	Founder	6.2yrs	US$834.28k	11.09% € 2.2m
Stephen Aselage	Independent Chairman of the Board	6.2yrs	US$104.95k	1.98% € 392.7k
Michelle Griffin	Independent Director	6.2yrs	US$88.08k	0% € 0
Stuart J. Swiedler	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Dunn	Independent Director	6.2yrs	US$84.95k	0.11% € 22.2k
Thomas Fleming	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jason Amello	Independent Director	6.2yrs	US$83.08k	0% € 0
Marlene Haffner	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gerard Berry	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens

6.2yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van P6NP wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Acer Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Acer Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Insufficient new directors

Acer Therapeutics Inc., Annual General Meeting, May 20, 2022

Insufficient new directors

Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer

Recent updates

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq

Acer Therapeutics Announces Full Enrollment of Phase 2A Trial of Acer-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Acer Therapeutics Inc. Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Acer Therapeutics Inc. announced that it has received $1.5 million in funding

Insufficient new directors

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Inc. Announces Receipt of Notice of Allowance of US Patent Application Covering Kit Comprising Phenylbutyrate and Sodium Benzoate

Acer Therapeutics Inc. Announces Expansion of Acer-801 (Osanetant) Development Indications to Include Post-Traumatic Stress Disorder

First half 2022 earnings released: US$0.82 loss per share (vs US$0.54 loss in 1H 2021)

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

Acer Therapeutics Inc. Resubmittes the ACER-001 New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Acer Therapeutics Not Yet Received Decision from the U.S. Food and Drug Administration on ACER-001

Acer Therapeutics Receives a Letter from the Listing Qualifications Department Staff of the Nasdaq Stock Market Regarding Minimum Market Value of Listed Securities

First quarter 2022 earnings released: US$0.64 loss per share (vs US$0.33 loss in 1Q 2021)

Insufficient new directors

Acer Therapeutics Inc. Provides an Update on the Recent Corporate Developments

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Acer Therapeutics Inc., Annual General Meeting, May 20, 2022

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Acer Therapeutics’ EDSIVO Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

Acer Therapeutics Enrolls First Patient in Its Phase 2A Clinical Trial of Acer-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Insufficient new directors

Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Acer Therapeutics Inc. Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Forecast to breakeven in 2023

Insufficient new directors

Insufficient new directors

Acer Therapeutics Plans Clinical Trial for Edsivo Following Type B FDA Meeting

Acer Expands Its Predator Gaming Portfolio with Three New HDR Monitors

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Acer Therapeutics Inc. Announces Update on Settlement of Derivative Suits

Acer Therapeutics Inc. Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

Relief Therapeutics and Acer Therapeutics Sign Option Agreement to Pursue a Potential Collaboration and License Arrangement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

New 90-day high: €3.04

Acer Therapeutics Inc. Announces Publication of Additional Long-Term Data from COL3A1-Positive Vascular Ehlers-Danlos Syndrome (vEDS) Patients

New 90-day low: €1.94

New 90-day low - €2.04

New 90-day high - €4.36

Acer Therapeutics Inc. announced that it expects to receive $0.857493 million in funding

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell 2000 Dynamic Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Small Cap Completeness Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Microcap Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd